What causes cold hands and feet, and do the pills help? For Raynaud's, only a little

Cold hands and feet are usually nothing more than the body doing its job — narrowing blood flow to the extremities to keep the core warm. But when the fingers or toes reliably turn white, then blue, then red in the cold or under stress, that pattern has a name and, for many people, a treatment that turns out to help less than they might hope. The condition is Raynaud's phenomenon, and the drugs most often prescribed for it clear a surprisingly low bar in the trials [s1].

What Raynaud's is

Primary Raynaud's phenomenon is a common condition characterised by an exaggerated vasospastic response to cold or emotion: classically the digits — fingers and toes — turn white, then blue, then red [s1]. The "primary" form occurs on its own, without an underlying disease driving it [s1] [s2]. A "secondary" form can accompany other conditions, particularly connective tissue diseases, and tends to be more serious [s2]. Most cold hands and feet are neither — they are ordinary temperature regulation — which is part of why distinguishing a benign chill from Raynaud's, and primary from secondary, is a job for clinical assessment rather than a symptom checker [s2].

What the drug evidence shows

Calcium channel blockers are the most commonly prescribed drugs for people with primary Raynaud's phenomenon [s1]. The 2016 Cochrane review that tested them included seven randomised trials with 296 participants; four trials examined nifedipine and the rest nicardipine, mostly against placebo [s1]. The headline finding is candid: treatment with oral calcium channel blockers was minimally effective at decreasing the frequency of attacks, with a standardised mean difference of 0.23 (95% confidence interval 0.08 to 0.38, P = 0.003) [s1]. Translated into something concrete, that works out to 1.72 fewer attacks per week (95% CI 0.60 to 2.84) on the drugs than on placebo [s1].

On the other outcomes, the drugs looked weaker still. One trial of 60 participants reported a mean attack-severity score of 1.55 on placebo versus 1.36 on nicardipine — a difference of about 0.2 — suggesting little effect on how bad each attack was [s1]. Physiological measurements of blood flow, tested in five trials with varied methods, showed no statistically significant differences between drug and placebo [s1]. The one clearly favourable result came from participants' own judgement: in one nifedipine trial, 33% of people on placebo reported improvement in symptoms against 73% on the drug (P < 0.001) [s1]. The evidence was rated moderate for the number of attacks and lower for other outcomes [s1].

Set against that modest benefit is a real cost in side effects. Calcium channel blockers were associated with a number of adverse reactions, including headaches, flushing and oedema — swelling [s1]. For some people the trade of a couple of fewer attacks a week against daily headaches will not be worth it; for others, with frequent or disabling episodes, it may be.

What actually helps day to day

The trials say the pills do something, but not much, which puts the emphasis back on the non-drug basics. The standard advice for Raynaud's centres on keeping the whole body warm — not just gloves and warm socks but avoiding sudden cold and the triggers that set off an attack — and on not smoking, because it narrows blood vessels [s2]. Managing stress matters too, since emotion as well as cold can provoke the vasospasm [s1] [s2].

What it adds up to

For cold, colour-changing fingers and toes that fit the Raynaud's pattern, the evidence is a useful corrective to expectations: calcium channel blockers are the mainstay, but they are minimally effective on the measure that matters most — how often attacks happen — and they carry side effects [s1]. That is not a reason to dismiss them, particularly for people whose attacks are frequent, but it is a reason to weight warmth, trigger avoidance and not smoking heavily in the plan [s2].

Two limits sit underneath all this. The Cochrane review covered only primary Raynaud's and a modest number of small trials, so the precise size of the benefit is uncertain [s1]. And colour change in the digits — especially if it starts later in life, affects the fingers unevenly, or comes with skin changes or sores — can signal the secondary form and warrants medical assessment rather than self-treatment [s2]. This article describes what the evidence shows, not what any individual should take.